Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225121 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT00225121 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 121 participants.
The verdict
NCT00225121, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.
Interventions
- DRUG PF-00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2005-10-11 |
| Est. Completion | 2010-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225121
The ClinicalTrials.gov registry entry for NCT00225121 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-00299804 is the first listed.
NCT00225121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225121 about?
NCT00225121 is a clinical study titled "Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors". The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.
What is the current status of trial NCT00225121?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2005-10-11. Estimated completion is 2010-09-23.
What interventions are being tested in trial NCT00225121?
The interventions under investigation include: PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT00225121?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.